88 related articles for article (PubMed ID: 36922937)
1. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma.
Yi H; Yan X; Luo Q; Yuan L; Li B; Pan W; Zhang L; Chen H; Wang J; Zhang Y; Zhai Y; Qiu MZ; Yang DJ
J Exp Clin Cancer Res; 2018 May; 37(1):97. PubMed ID: 29716622
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 4-imidazolidinone-containing compounds as potent inhibitors of the MDM2/p53 interaction.
Lin Z; Liu C; Yan Z; Cheng J; Wang X; Zhou F; Lyu X; Zhang S; Zhang D; Meng X; Zhao Y
Eur J Med Chem; 2024 Apr; 270():116366. PubMed ID: 38581730
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction.
Gasparoli L; Virely C; Tsakaneli A; Che N; Edwards D; Bartram J; Hubank M; Pal D; Heidenreich O; Martens JHA; De Boer J; Williams O
Haematologica; 2024 Apr; 109(4):1069-1081. PubMed ID: 37794795
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the mouse double minute 4 gene causes changes in cell cycle control in a human mesothelial cell line responsive to ultraviolet radiation exposure.
Bunderson-Schelvan M; Erbe AK; Schwanke C; Pershouse MA
Environ Mol Mutagen; 2009 Dec; 50(9):753-9. PubMed ID: 19472317
[TBL] [Abstract][Full Text] [Related]
6. A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.
Kulkarni YM; Chambers E; McGray AJ; Ware JS; Bramson JL; Klinke DJ
Integr Biol (Camb); 2012 Aug; 4(8):925-36. PubMed ID: 22777646
[TBL] [Abstract][Full Text] [Related]
7. MDM2: current research status and prospects of tumor treatment.
Yao Y; Zhang Q; Li Z; Zhang H
Cancer Cell Int; 2024 May; 24(1):170. PubMed ID: 38741108
[TBL] [Abstract][Full Text] [Related]
8. AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.
Sahin I; Zhang S; Navaraj A; Zhou L; Dizon D; Safran H; El-Deiry WS
Cell Death Discov; 2020; 6():57. PubMed ID: 32655895
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis.
Zhu H; Jia Z; Trush MA; Li YR
React Oxyg Species (Apex); 2016; 2(4):308-314. PubMed ID: 29721548
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation.
Aziz YMA; Lotfy G; Said MM; El Ashry ESH; El Tamany ESH; Soliman SM; Abu-Serie MM; Teleb M; Yousuf S; Dömling A; Domingo LR; Barakat A
Front Chem; 2021; 9():735236. PubMed ID: 34970530
[TBL] [Abstract][Full Text] [Related]
11. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
Wang W; Albadari N; Du Y; Fowler JF; Sang HT; Xian W; McKeon F; Li W; Zhou J; Zhang R
Pharmacol Rev; 2024 May; 76(3):414-453. PubMed ID: 38697854
[TBL] [Abstract][Full Text] [Related]
12. Pten knockout affects drug resistance differently in melanoma and kidney cancer.
Brodaczewska K; Majewska A; Filipiak-Duliban A; Kieda C
Pharmacol Rep; 2023 Oct; 75(5):1187-1199. PubMed ID: 37673853
[TBL] [Abstract][Full Text] [Related]
13. MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia.
Lerma Clavero A; Boqvist PL; Ingelshed K; Bosdotter C; Sedimbi S; Jiang L; Wermeling F; Vojtesek B; Lane DP; Kannan P
Sci Rep; 2023 Mar; 13(1):4583. PubMed ID: 36941277
[TBL] [Abstract][Full Text] [Related]
14. The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth
Ingelshed K; Spiegelberg D; Kannan P; Påvénius L; Hacheney J; Jiang L; Eisinger S; Lianoudaki D; Lama D; Castillo F; Bosdotter C; Kretzschmar WW; Al-Radi O; Fritz N; Villablanca EJ; Karlsson MCI; Wermeling F; Nestor M; Lane DP; Sedimbi SK
Cancer Res Commun; 2022 Sep; 2(9):1075-1088. PubMed ID: 36922937
[TBL] [Abstract][Full Text] [Related]
15. A truncated isoform of the PP2A B56gamma regulatory subunit reduces irradiation-induced Mdm2 phosphorylation and could contribute to metastatic melanoma cell radioresistance.
Koma YI; Ito A; Watabe K; Kimura SH; Kitamura Y
Histol Histopathol; 2004 Apr; 19(2):391-400. PubMed ID: 15024700
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
17. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
18. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
